New hope for tough seizures: RAP-219 safety trial opens

NCT ID NCT07219407

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 26 times

Summary

This study tests the long-term safety of an experimental drug called RAP-219 in 30 adults with refractory focal epilepsy—seizures that don't respond well to current treatments. Participants must have completed a prior RAP-219 study. The main goal is to track side effects, while also measuring how well the drug controls seizures over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 770300, United States

  • Cleveland Clinic Foundation

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Consultants in Epilepsy and Neurology, PLLC

    RECRUITING

    Boise, Idaho, 83702, United States

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • NYU Langone Comprehensive Epilepsy Center

    RECRUITING

    New York, New York, 10016, United States

  • University of Pennsylvania - Department of Neurology

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.